Is ZCC is a long way off from topline results from where it now stands for it to be a buyout candidate? Don't know!
ClinicalTrials.gov Identifier: NCT03901469
Official Title: |
A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer |
Actual Study Start Date : |
June 26, 2019 |
Estimated Primary Completion Date : |
September 2021 |
Estimated Study Completion Date : |
January 2022 |
Koo